Shuqi Chen

Shuqi Chen

Auto-generated profile, based on publicly available information

Shuqi Chen

Faculty of Pharmacy and Pharmaceutical Sciences

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 1999 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
SCShuqi Chen
Shuqi Chen
TSTimothy A. Springer
Timothy A. Springer
Wall shear stress in postcapillary venules varies widely within and between tissues and in response to inflammation and exercise. However, the speed at which leukocytes roll in vivo has been shown to be almost constant within a wide range of wall shear stress, i.e., force on the cell. Similarly, rolling velocities on purified selectins and their ligands in vitro tend to plateau. This may be important to enable rolling leukocytes to be exposed uniformly to activating stimuli on endothelium, independent of local hemodynamic conditions. Wall shear stress increases the rate of dissociation of individual selectin–ligand tether bonds exponentially (1, 4) thereby destabilizing rolling. We find that this is compensated by a shear-dependent increase in the number of bonds per rolling step. We also find an increase in the number of microvillous tethers to the substrate. This explains (a) the lack of firm adhesion through selectins at low shear stress or high ligand density, and (b) the stability of rolling on selectins to wide variation in wall shear stress and ligand density, in contrast to rolling on antibodies (14). Furthermore, our data successfully predict the threshold wall shear stress below which rolling does not occur. This is a special case of the more general regulation by shear of the number of bonds, in which the number of bonds falls below one.

28 April 2025 in Journal of Chemical Education
Verified
Journal Article
Closed access
EYElizabeth Yuriev
Elizabeth Yuriev
MBMatthew G. Burton
Matthew G. Burton
DKDrew Knott
Drew Knott
ATAlice E. Terrill
Alice E. Terrill
NJNeale R. C. Jackson
Neale R. C. Jackson
SCShuqi Chen
Shuqi Chen

23 October 2020 in Australian Journal of Chemistry
Verified
Journal Article
Closed access
PDF file
SCShuqi Chen
Shuqi Chen
BFBernard Flynn
Bernard Flynn
The iodocyclisation of alkynes bearing tethered nucleophiles is a highly effective method for the construction and diversification of heterocycles. A key limitation to this methodology is the 5-endo-dig iodocyclisation of alkynes that have an unfavourable electronic bias for electrophilic cyclisation. These tend to direct electrophilic attack of the iodonium atom to the wrong carbon for cyclisation, thus favouring competing addition reactions. Using our previously determined reaction conditions for the 5-endo-dig iodocyclisations of electronically resistant alkynes, we have achieved efficient synthetic access to 2-carboxy (and sulfoxy)-3-iodobenzo[b]thiophenes. The corresponding benzo[b]furans and indoles were not accessible under these conditions. This difference may arise due to the availability of a radical mechanism in the case of iodobenzo[b]thiophenes. The 2-carboxy functionality of the iodocyclised products can be further employed in iterative alkyne-coupling iodocyclisation reactions, where the carboxy group or an imine (Schiff base) partakes in a second iodocyclisation to generate a lactone or pyridine ring.

3 November 2022 in Chemistry – A European Journal
Verified
Journal Article
Open access
SCShuqi Chen
Shuqi Chen
DPDaniel L. Priebbenow
Daniel L. Priebbenow
JSJulie SOMKHIT
Julie SOMKHIT
CSCarmen V. Scullino
Carmen V. Scullino
KAKeli Agama
Keli Agama
BFBernard Flynn
Bernard Flynn
Polynucleotides, DNA and RNA (mRNA and non‐coding RNAs) are critically involved in the molecular pathways of disease. Small molecule binding interactions with polynucleotides can modify functional polynucleotide topologies and/or their interactions with proteins. Current approaches to library design (lead‐like or fragment‐like libraries) are based on protein‐ligand interactions and often include careful consideration of the 3‐dimensional orientation of binding motifs and exclude π‐rich compounds (polyfused aromatics) to avoid off‐target R/DNA interactions. In contrast to proteins, where π,π‐interactions are weak, polynucleotides can form strong π,π‐interactions with suitable π‐rich ligands. To assist in designing a polynucleotide‐biased library, a scaffold‐divergent synthesis approach to polyfused aromatic scaffolds has been undertaken. Initial screening hits that form moderately stable polynucleotide‐ligand‐protein ternary complexes can be further optimized through judicious incorporation of substituents on the scaffold to increase protein‐ligand interactions. An example of this approach is given for topoisomerase‐1 (TOP1), generating a novel TOP1 inhibitory chemotype.

1 July 2021 in Cancer Research
Verified
Journal Article
Closed access
JWJincheng Wu
Jincheng Wu
SCShuqi Chen
Shuqi Chen
GBGuillaume Baneyx
Guillaume Baneyx
AMAnne-Laure Marchal
Anne-Laure Marchal
DQDavid S. Quinn
David S. Quinn
JMJennifer Marie Mataraza
Jennifer Marie Mataraza
Background: The CSF-1/CSF-1R (colony-stimulating factor-1) pathway plays a significant role in the tumor microenvironment via regulation of tumor-associated macrophages (TAMs). Lacnotuzumab (MCS110) is a humanized monoclonal antibody against CSF-1. Lacnotuzumab may counteract the tumor suppressive microenvironment induced by CSF-1, potentially enhancing the efficacy of PD-1 inhibition. Methods: MCS110Z2102 is a phase 1b/2 study in cancer patients with advanced malignancies treated by lacnotuzumab combined with the PD-1 inhibitor spartalizumab. Eligible patients with previously treated advanced/metastatic solid tumors received 1, 3, 5, 7.5 and 10 mg/kg intravenous doses of lacnotuzumab in dose escalation combined with 100 mg or 300 mg of spartalizumab administered every 3 weeks. Then, the selected recommended phase 2 dose (RP2D, 7.5 mg/kg lacnotuzumab in combination with 300 mg spartalizumab every 3 weeks) was explored in 4 expansion groups of pancreatic cancer, triple-negative breast cancer (TNBC), endometrial cancer (EC) and malignant melanoma. Here, we report flow cytometric, circulating total CSF1 in plasma and gene expression profiling analyses as evidence of on-target pharmacodynamic effects of lacnotuzumab + spartalizumab in treated patients. Results: The combination of lacnotuzumab and spartalizumab increased the levels of circulating total CSF-1 in plasma, thereby suggesting target engagement and selectively decreased peripheral CSF-1R-expressing intermediate and nonclassical monocytes, at all doses tested. Gene expression profiling by RNA-sequencing in paired biopsies showed down-regulation of macrophage associated genes in patients treated with lacnotuzumab + spartalizumab. In addition, the upregulation of cytotoxic T cell gene signatures was observed. A limited antitumor activity was observed: 2 pancreatic cancer, 1 TNBC and 2 EC patients had a confirmed partial response over 141 patients treated. Conclusions: Flow cytometric, circulating total CSF1 in plasma and gene expression profiling results demonstrated that targeting CSF-1 with lacnotuzumab in the periphery and tumor microenvironment leads to decrease in monocytes and reduced expression of macrophage associated genes in patients with advanced cancers. Unfortunately, in the heavily pretreated patient populations studied in this trial, only a limited clinical efficacy was demonstrated. Citation Format: Jincheng Wu, Shuqi Chen, Guillaume Baneyx, Anne-Laure Marchal, David S. Quinn, Miguel Martin, Andres Cervantes, Janna Sand-Dejmek, Jennifer Marie Mataraza. On-target peripheral and tumor immune microenvironment modulation in patients treated with lacnotuzumab (anti-CSF1, MCS110) + spartalizumab [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr LB061.